findmyKOL

Michael Davidson, MD

Enriched profile

Clinical Professor of Medicine; Director, Lipid Clinic and Preventive Cardiology · University of Chicago Medicine

ORCIDNone on fileNPI
Region🇺🇸 Chicago, IL · Midwest · United StatesSpecialtyCardiovascular DiseaseFocusCoronary Artery Disease / ACS+1
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2025Online presenceverified 2026Payments2021–2025NIH funding2024–2024Why? →

Michael Davidson is Clinical Professor of Medicine; Director, Lipid Clinic and Preventive Cardiology at University of Chicago Medicine. ClinicalTrials.gov lists 20 registered studies with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Michael H. Davidson is Clinical Professor of Medicine at University of Chicago Medicine / Pritzker School of Medicine. The public record shows 116 publications with 6,087 citations (h-index 27), centered on Coronary Artery Disease / ACS, Dyslipidemia / Lipid Disorders. It also documents an investigator role on 20 registered clinical trials, industry payments reported by 13 companies, 1 NIH-funded awards (2024–2024).

  • Top research focus: Coronary Artery Disease / ACS
  • 20 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 13 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Dyslipidemia / Lipid Disorders5 trialsHypertriglyceridemia5 trialsCoronary Artery Disease / ACS3 trialsStroke2 trialsCoronary Artery Disease2 trialsSchizophrenia2 trialsDyslipidemias2 trialsCardiovascular Diseases1 trialMyocardial Infarction1 trialAtherosclerosis1 trialVascular Diseases1 trialVirus Diseases1 trialCytomegalovirus Infections1 trialChlamydia Infections1 trialInfarction1 trialHelicobacter Infections1 trialPsychotic Disorders1 trialHyperglycemia1 trialDepression (MDD)1 trial

Research focus

OpenAlex concept fingerprint
Coronary Artery Disease / ACSDyslipidemia / Lipid Disorders

Drugs & molecules

across trials, industry payments and publications
Repathageneric · EvolocumabClinical trialsIndustry payments105PublicationsNexletolgeneric · Bempedoic acidClinical trialsIndustry payments13PublicationsNexlizetgeneric · Bempedoic acid / ezetimibeClinical trialsIndustry payments12Publications

Works with

trial sponsors and companies reporting payments
Amgen Inc.Clinical trialsIndustry payments105Esperion Therapeutics, Inc.Clinical trialsIndustry payments13Novo Nordisk IncClinical trialsIndustry payments8

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
27h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
20clinical trials

Investigator role on registered studies.

View trials
13companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 2024–2024

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 20 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

13 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cardiovascular

    94.5%
    PCSK9 Inhibitor36.2%
    Repatha Sureclick78%Praluent Pen22%
    Part D43 patients
    Statin23.3%
    Rosuvastatin Calcium73%Atorvastatin Calcium27%
    Part D41 patients
  • Metabolism & gastrointestinal

    3.8%
    SGLT2 inhibitor2.1%
    Jardiance100%
    Part D<11 patients
    Biguanide (metformin)1.8%
    Metformin Hcl100%
    Part D<11 patients
  • Hormonal (systemic)

    1.6%
    l-Thyroxine1.6%
    Levothyroxine Sodium100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

1 NIH research award on record, funded 20242024 per NIH RePORTER. The latest:

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/michael-davidson-md-886a4265

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com
  • Other

    uchicagomedicine.org/find-a-physician/physician/michael-h-davidson

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org
  • X / Twitter

    x.com/mdavidsonmd

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →x.com

Mentions by others

where others cite or feature them
  • Other

    healio.com/cme/lipidcme/safety-and-efficacy-of-ldl-c-reduction/20241031/1-lipid-legends-with-your-host-dr-ronald-codario/overview

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healio.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record
  • MD

    The Ohio State University College of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org
  • BA/MS

    Northwestern University

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →abcentra.com
  • Board Certified

    Internal Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org
  • Board Certified

    Cardiovascular Disease

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org
  • Board Certified

    Clinical Lipidology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →abcentra.com

Editorial & leadership roles

journal and society appointments
  • Past President

    National Lipid Association

    2011
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org
  • Fellow

    American College of Cardiology (FACC)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →9690c.iqanda-cme.com
  • Fellow

    National Lipid Association (FNLA)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →9690c.iqanda-cme.com
3 more roles behind the reveal.Reveal →

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Founding CEO/CMO

    Corvidia Therapeutics

    2020
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →abcentra.com
  • Co-founder/CMO

    Omthera Pharmaceuticals

    2013
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →abcentra.com
  • Founder

    Chicago Center for Clinical Research

    1996
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →abcentra.com

Media & interviews

press, podcasts and appearances
1 more media item behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.